美港探案2019-10-10 23:53
$达美航空(DAL)$ 跌逾3%,尽管Q3盈利超预期;$Ra Pharmaceuticals(RARX)$ 暴涨逾100%,UCB将以21亿美元收购前者;PG&E大跌30%,因破产法官允许Elliot提出重组计划;3B家居大涨22%,任命前塔吉特高管为新任CEO;$如涵(RUHN)$ 招股书被指误导投资人,在美一个月遭逾10宗集体诉讼。查看全文
chuminhua2019-10-10 21:11
$Ra Pharmaceuticals(RARX)$ $UCB(UCBJY)$ 10/10,UCB宣布以每股48美元,总计21亿美元现金收购Ra Pharma。前一天Ra Pharma的收盘价为22.70美元。Ra的C5抑制剂zilucoplan正在开展治疗重症肌无力(MG)的III期临床,该产品有望与Alexion的Soliris竞争。查看全文
英为财情Investing2019-10-10 20:43
$达美航空(DAL)$ 跌逾3%,尽管Q3盈利超预期;$Ra Pharmaceuticals(RARX)$ 暴涨逾100%,UCB将以21亿美元收购前者;PG&E大跌30%,因破产法官允许Elliot提出重组计划;3B家居大涨22%,任命前塔吉特高管为新任CEO;$如涵(RUHN)$ 招股书被指误导投资人,在美一个月遭逾10宗集体诉讼。查看全文
淘沙见金2019-10-10 18:42
$Ra Pharmaceuticals(RARX)$ EU pharma quite active in H2 so far on M&As
July: Boehringer Ingelheim / Amal Tx, Zambon / Breath Tx
Aug: Bayer / BlueRock Tx
Sept: Lundbeck / Alder Biopharma, SOBI / Dova Pharma
Oct: UCB / Ra Pharma
延续了最近欧洲药企来抄底的主查看全文
牛唐2019-03-16 14:58
$Akari Therapeutics(AKTX)$ FDA同意coversin在HSCT-TMA适应症的关键阶段的实验设计,引发了翻倍的增长,如果后续数据好的话,未来市值有望跟相$Ra Pharmaceuticals(RARX)$ 、$奥麦罗制药(OMER)$ 相比查看全文
淘沙见金2017-11-09 11:56
(个人笔记,欢迎讨论)
Apellis Pharmaceutical $Apellis Pharmaceuticals, Inc.(APLS)$ 是一家生物制药临床研发公司,头号在研药物APL2是补体分子C3抑制剂,用于治疗各种自身免疫性疾病如年龄相关性黄斑变性(AMD),PNH,自身免疫性溶血性贫血(Autoimmune hemolytic anemia,AIHA)和年龄相关...查看全文
$Ra Pharmaceuticals(RARX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-042448 Act: 33 Size: 25 KB 网页链接
$Ra Pharmaceuticals(RARX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-042454 Act: 33 Size: 25 KB 网页链接
$Ra Pharmaceuticals(RARX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-042455 Act: 33 Size: 25 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 8-K Current report, items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, and 9.01 Accession Number: 0001104659-20-042433 Act: 34 Size: 572 KB 网页链接
$Ra Pharmaceuticals(RARX)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001104659-20-042436 Act: 33 Size: 42 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-20-000136 Act: 34 Size: 2 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 8-K Current report, item 8.01 Accession Number: 0001104659-20-040735 Act: 34 Size: 20 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 内部交易: 2020-03-16,Chief Medical Officer,Farzaneh-Far Ramin ,卖出,10595普通股, $45.16
$Ra Pharmaceuticals(RARX)$ 内部交易: 2020-03-16,Chief Medical Officer,Farzaneh-Far Ramin ,期权,10595普通股, $5.60
$Ra Pharmaceuticals(RARX)$ 内部交易: 2020-03-17,See Remarks,Ricardo Alonso ,卖出,2288普通股, $44.25